Synthesis and antitumor activities of novel 5-deazaflavin-sialic acid conjugate molecules

Bioorganic and Medicinal Chemistry

Volumn 8, Issue 8, 2000, Pages 2027-2035

  Ikeuchi, Yoshihiro ^a   Sumiya, Motoko ^a   Kawamoto, Tetsuji ^a   Akimoto, Naoshige ^a   Mikata, Yuji ^b   Kishigami, Maki ^b   Yano, Shigenobu ^b   Sasaki, Takuma ^c   Yoneda, Fumio ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NARA WOMEN'S UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 DEAZAFLAVIN SIALIC ACID; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN KB; CHROMATOGRAPHY; CONJUGATE; CONTROLLED STUDY; DRUG SYNTHESIS; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA L 1210; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS; CIRCULAR DICHROISM; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVINS; HUMANS; KB CELLS; LEUKEMIA L1210; MICE; MOLECULAR STRUCTURE; SIALIC ACIDS;

EID: 0033855937     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(00)00124-3     Document Type: Article

References (45)

1. In Sialic Acids, Chemistry, Metabolism and Function; Schauer, R. Ed.; Springer-Verlag, Wien, 1982.
2. a) Kelm, S.; Schauer, R.; Crocker, P. R. Glycoconj. J. 1996, 13, 913.
3. b) Liu, T. Y.; Gotschlich, E. C.; Egan, W.; Robbins, J. B. J. Infect. Dis. Suppl. 1977, 136, S71.
4. c) Egan, W.; Liu, T. Y.; Dorow, D.; Cohen, J. S.; Robbins, J. D.; Gotschlich, E. C. Robbins, J. B. Biochemistry 1977, 16, 3687.
5. a) Schauer, R. Adv. Exp. Med. Biol. 1988, 228, 47.
6. b) Kelm, S.; Shukla, A. K.; Paulson, J. C.; Schauer, R. Carbohydr. Res. 1986, 149, 59.
7. a) Varki, A.; Hooshmand, F.; Diaz, S.; Varki, N. M.; Hedrick, S. M. Cell 1991, 65, 65.
8. b) Saito, M. Adv. Lipid. Res. 1993, 25, 303.
9. c) Tsuji, S.; Yamashita, T.; Nagai, Y. J. Biochem. 1988, 104, 498.
10. a) Hakomori, S. Acta. Anat. 1998, 161, 79.
11. b) Hakomori, S. Cancer Res. 1996, 56, 5309.
12. c) Hakomori, S. Chem. Phys. Lipids, 1986, 42, 209.
13. a) Sharon, N.; Lis, H. Sci. Am., 1993, 82.
14. b) Tsuji, S.; Yamashita, T.; Tanaka, M.; Nagai, Y. J. Neurochem. 1988, 50, 414.
15. c) Kijima-Suda, I.; Miyazawa, T.; Itoh, M.; Toyoshima, S.; Osawa, T. Cancer Res. 1988, 48, 3728.
16. a) Sato, S.; Fujita, S.; Furuhata, K.; Ogura, H.; Yoshimura, S.; Itoh, M.; Shitori, Y. Chem. Pharm. Bull. 1987, 35, 4043.
17. b) Suzuki, K.; Kobayashi, R.; Furuhata, K.; Ogura, H. Chem. Pharm. Bull. 1990, 38, 2083.
18. a) Kijima, I.; Ezawa, K.; Toyoshima, S.; Furuhata, K.; Ogura, H., Osawa, T. Chem. Pharm. Bull. 1982, 30, 3278.
19. b) Kijima-Suda, I.; Toyoshima, S.; Itoh, M.; Furuhata, K.; Ogura, H.; Osawa, T. Chem. Pharm. Bull. 1985, 33, 730.
20. c) Ogura, H.; Fujita, H.; Furuhata, K.; Itoh, M.; Shitori, Y. Chem. Pharm. Bull. 1986, 34, 1479.
21. a) Kleineidam, R. G.; Furuhata, K.; Ogura, H.; Schauer, R. Biol. Chem. Hoppe-Seyler, 1990, 371, 715.
22. b) Furuhata, K.; Ogura, H. Chem. Pharm. Bull. 1989, 37, 2037.
23. Furuhata K., Komiyama K., Ogura H., Hata T. Chem. Pharm. Bull. 39:1991;255.
24. Takahashi T., Tsukamoto H., Yamada H. Bioorg. Med. Chem. Lett. 8:1998;113.
25. Sakaguchi M., Webb M.W., Agrawal C. J. Med. Chem. 25:1982;1339.
26. Kawamoto T., Ikeuchi Y., Hiraki J., Eikyu Y., Shimizu K., Tomishima M., Bessho K., Yoneda F., Mikata Y., Nishida M., Ikehara K., Sasaki T. Bioorg. Med. Chem. Lett. 5:1995;2109.
27. Kawamoto T., Ikeuchi Y., Hiraki J., Eikyu Y., Shimizu K., Tomishima M., Bessho K., Yoneda F., Mikata Y., Nishida M., Ikehara K. Bioorg. Med. Chem. Lett. 5:1995;2115.
28. Kanaoka Y., Ikeuchi Y., Kawamoto T., Bessho K., Akimoto N., Mikata Y., Nishida M., Yano S., Sasaki T., Yoneda F. Bioorg. Med. Chem. 6:1998;301.
29. Mikata Y., Kishigami M., Nishida M., Yano S., Kawamoto T., Ikeuchi Y., Yoneda F. Bioorg. Med. Chem. Lett. 9:1999;2141.
30. Kalir A. Org. Synth. 46:1966;81.
31. Nagamatsu, T.; Hashiguchi, Y.; Yoneda, F. J. Chem. Soc., Perkin Trans. 1 1984, 561.
32. Heslin, J. C.; Moody, C. J. J. Chem. Soc. Perkin Trans. 1 1988, 1417.
33. a) Ogura, H.; Furuhata, K.; Itoh, M.; Shitori, Y. Carbohydr. Res., 1986, 158, 37.
34. b) Kuhn, R.; Lutz, P.; Macdonald, D. L. Chem. Ber., 1966, 99, 611.
35. Nakamura M., Furuhata K., Ogura H. Chem. Pharm. Bull. 36:1988;4807.
36. Yoneda F., Mori K., Sakuma Y. J. Heterocyclic Chem. 19:1982;945.
37. Dabrowski U., Friebolin H., Brossmer R., Supp M. Tetrahedron Lett. 48:1979;4637.
38. Okamoto K., Kondo T., Goto T. Bull. Chem. Soc. Jpn. 60:1987;637.
39. Estimated Δδ|H(9′)-H(9)| values of the compounds 1-3: 1a, <0.19 ppm; 1b, 0.33 ppm; 2a, 0.25-0.35 ppm; 2b, 0.70-0.93 ppm; 3a, 0.07-0.21 ppm; 3b, 0.96-1.14 ppm.
40. Hydrolysis of acetate and methyl ester of the sialic acid moiety of compounds 1-3 were not essentially observed under the reaction condition employed.
41. Ogura H., Furuhata K. Tetrahedron Lett. 22:1981;4265.
42. Edmondson D.E., Tollin G. Biochemistry. 10:1971;113.
43. Carmichael J., DeDraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Cancer Res. 47:1987;936.
44. Tanaka M., Matsuda A., Terao T., Sasaki T. Cancer Lett. 64:1992;67.
45. 50>100 μM) than those of 1-3. This result would probably be accounted by lower permeability of the deprotected compounds of 1-3 into tumor cells. Similar examples of antitumor activities of protected and deprotected sialosylphenyl mitomycin C derivatives are reported in ref 12.